drugset / Trial / NCT01962103

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

NCT01962103 ↗

Phase 1/2 Completed 107 enrolled Celgene Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid tumors, and to see if it works to treat these solid tumors in children and young adults (in Phase 1 ≤ 18 years old and in Phase 2 ≤ 24 years old). After the final dose has been chosen, patients will be enrolled according to the specific solid tumor type, (neuroblastoma, rhabdomyosarcoma, or Ewing's sarcoma), to see how nab-paclitaxel works in treating these tumors.

Timeline

Start
2013-12-04
Primary completion
2017-12-05
Completion
2018-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Nab-paclitaxel Small molecule 11.5 mg/kg Intravenous
Subject Nab-paclitaxel Small molecule 120 mg/m2 Intravenous
Subject Nab-paclitaxel Small molecule 150 mg/m2 Intravenous
Subject Nab-paclitaxel Small molecule 180 mg/m2 Intravenous
Subject Nab-paclitaxel Small molecule 210 mg/m2 Intravenous
Subject Nab-paclitaxel Small molecule 240 mg/m2 Intravenous
Subject Nab-paclitaxel Small molecule 270 mg/m2 Intravenous